Latest Healthcare News

Visionflex Group delivered a standout Q4 FY25, posting $2.1 million in cash receipts and securing transformative contracts that underpin its expanding virtual healthcare footprint.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Lumos Diagnostics Holdings Limited has had its ASX trading suspension lifted following news of a strategic material agreement, signaling potential growth ahead.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

EBR Systems has received preliminary approval from the U.S. Centers for Medicare & Medicaid Services for outpatient reimbursement of its WiSE® CRT System, marking a major step toward broader hospital adoption.

Lumos Diagnostics has voluntarily suspended its ASX trading pending a market announcement about strategic agreements, signaling potential shifts in its business trajectory.

Pacific Edge reports steady demand for its Cxbladder cancer diagnostic tests despite losing Medicare coverage and transitioning US customers to a new test. The company is advancing clinical evidence and a $21 million capital raise to support growth and regain coverage.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

HITIQ Limited is set to debut its PROTEQT concussion management system in the UK on August 4, 2025, uniquely integrating with NHS 111 telehealth services to offer free medical guidance. This launch marks HITIQ’s first international consumer market entry and a strategic step in its global expansion.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.